Key statistics
On Tuesday, MannKind Corp (NNFN:FRA) closed at 6.69, -4.40% below its 52-week high of 7.00, set on Nov 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.69 |
---|---|
High | 6.69 |
Low | 6.69 |
Bid | 6.61 |
Offer | 6.72 |
Previous close | 6.88 |
Average volume | 1.72k |
---|---|
Shares outstanding | 275.00m |
Free float | 269.90m |
P/E (TTM) | 101.52 |
Market cap | 1.99bn USD |
EPS (TTM) | 0.0711 USD |
Data delayed at least 15 minutes, as of Nov 12 2024 07:11 GMT.
More ▼
Announcements
- MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
- MannKind to Present at 2024 UBS Healthcare Conference
- MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
- MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
- More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
- MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
- MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
- MannKind to Present at Upcoming Conferences
- Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board
- MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
More ▼